Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Nature Communications|April 25, 2013
miR-155 regulates differentiation of brown and beige adipocytes via a bistable circuitYong Chen, Franziska Siegel, Stefanie Kipschull, et al.Journal of Experimental & Clinical Cancer Research : CR|February 8, 2014
Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspectiveNiels Eckstein, Lea Röper, Bodo Haas, et al.Molecular Metabolism|May 12, 2024
Sulfonylureas exert antidiabetic action on adipocytes by inhibition of PPARγ serine 273 phosphorylationBodo Haas, Moritz David Sebastian Hass, Alexander Voltz, et al.The Journal of Experimental Medicine|January 7, 2009
Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanomaRamin Massoumi, Silke Kuphal, Claus Hellerbrand, et al.Science Signaling|December 3, 2009
Protein kinase G controls brown fat cell differentiation and mitochondrial biogenesisBodo Haas, Peter Mayer, Katja Jennissen, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 11, 2013
Increased cGMP promotes healthy expansion and browning of white adipose tissueMichaela M Mitschke, Linda S Hoffmann, Thorsten Gnad, et al.Cancer Cell International|May 15, 2018
Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugsBodo Haas, Veronika Klinger, Christina Keksel, et al.Science Signaling|December 24, 2010
Cyclic GMP and protein kinase G control a Src-containing mechanosome in osteoblastsHema Rangaswami, Raphaela Schwappacher, Nisha Marathe, et al.Regulatory Toxicology and Pharmacology : RTP|July 11, 2025
Evaluating the lifetime cumulative dose as a basis for carcinogenic potency of nitrosamines - a key tenet underpinning less-than-lifetime approaches for establishing acceptable intake limitsSusan P Felter, Ashley M Mudd, David J Ponting, et al.Regulatory Toxicology and Pharmacology : RTP|May 16, 2024
Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA)Naomi L Kruhlak, Marianne Schmidt, Roland Froetschl, et al.Pageof 3